ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2026)

ARS Pharmaceuticals has reported Total Non-Current Liabilities for 5 years, with the latest figure at $221.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $221.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.8 million (changed N/A YoY) and the FY2025 annual result came in at $208.8 million, up 121.28% from the prior year.
• Total Non-Current Liabilities grew to $221.8 million in Q1 2026 per SPRY's latest filing, from $208.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $221.8 million in Q1 2026 and troughed at $8.5 million in Q4 2022.
• A 4-year average of $145.8 million and a median of $164.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities slumped 48.48% in 2022, then jumped 121.28% in 2025.
• Over 4 years, Total Non-Current Liabilities stood at $8.5 million in 2022, then jumped by 1003.7% to $94.4 million in 2024, then jumped by 121.28% to $208.8 million in 2025, then gained by 6.22% to $221.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $221.8 million, $208.8 million, and $221.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.